IL6R and congenital rubella syndrome: Since CRS can be successfully ameliorated with the IL-6R inhibitor tocilizumab (Grupp et al., 2013), investigators now have more experience in how to diagnose and manage CRS, and recently several reviews have highlighted and summarized these advances (Lee et al., 2014; Maude et al., 2014b; Xu and Tang 2014; Brudno and Kochenderfer 2016; Bonifant et al., 2016).